UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number 000-50797

 

 

MOMENTA PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

301 Binney Street

Cambridge, Massachusetts 02142

(617) 491-9700

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, par value $0.0001 per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

  Rule 12g-4(a)(1)     
  Rule 12g-4(a)(2)     
  Rule 12h-3(b)(1)(i)     
  Rule 12h-3(b)(1)(ii)     
  Rule 15d-6     
  Rule 15d-22(b)     

Approximate number of holders of record as of the certification or notice date: One (1)

Pursuant to the requirements of the Securities Exchange Act of 1934, Momenta Pharmaceuticals, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

    MOMENTA PHARMACEUTICALS, INC.
   

Date: October 13, 2020

   

By:

 

/s/Young Kwon

      Name:  Young Kwon
      Title:    Chief Financial and Business Officer

 

 

 

Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Momenta Pharmaceuticals Charts.
Momenta Pharmaceuticals (NASDAQ:MNTA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Momenta Pharmaceuticals Charts.